



Gene Comprehensive Nutrigenomic Report

Accession Number: #####

Report Generated: August 1, 2018

Specimen Received: ##/##/####

Created For: #####

DOB: ##/##/####

Female



Do not make any decisions about your health solely based on the information contained in this report.
Always consult with a licensed and experienced health practitioner when you receive this report.

– 46 – Female

(-/-) No clinical abnormality

(+/-) Heterozygous result

(+/-) Homozygous result

rsID	Gene	Genetic Result	Therapeutics Associated With Positive Result	Highly Recommended Therapeutics/Neurobiologix Formulas	Provider Discretion: As Needed Formula Recommendations	Lifestyle Recommendations	Laboratory Recommendations
Autophagy							
Autophagy Associated							
rs10210302	ATG16L1	+/+	Curcumin, Lithium Orotate, D-Chiro-Inositol, Catechins, Resveratrol, Caffeine, 12 Hour Fasting	N.A.S. Enhancer™ (NRF2 Autophagy SOD Support), Metabolic Stimulator™		Calorie Restriction, 12-15 Hour Fasting	Routine Blood Sugar, Insulin and Hb A1c
rs26538	ATG12	+/+					
rs510432	ATG5	+/+					
rs1007008	SMURF1	-/-					
rs2066845	NOD2 CARD15	+/-	Increase susceptibility to bacterial GI infections and Crohn's	Neuro-Immune Infection Control™, N.A.S. Enhancer™ (NRF2 Autophagy SOD Support)			Consider Microbiome Testing If GI Inflammation Present
rs2241880	ATG16L1	+/+					
rs104893875	PARK1 (alpha synuclein)	-/-	Curcumin, Lithium Orotate, D-Chiro-Inositol, Catechins, Resveratrol, Caffeine, 12-15 Hour Fasting		N.A.S. Enhancer™ (NRF2 Autophagy SOD Support), Metabolic Stimulator™, mTOR Inhibitors	Increased Risk of Parkinson's, Calorie Restriction, 12-15 Hour Fasting	
rs3798963	PARK2 (Parkin)	+/-					
rs45478900	PARK6 (PINK1)	-/-					
rs429358	APOE	-/-	Calorie Restriction, Routine 12-15 Hour Fasting, Increased Risk of Memory Disorders				
rs7412	APOE	-/-					

Summary for Autophagy

Highly Recommended Therapeutics/Neurobiologix Formulas

- **N.A.S. Enhancer™ (NRF2|Autophagy|SOD Support), Metabolic Stimulator™**
- **Neuro-Immune Infection Control™, N.A.S. Enhancer™ (NRF2|Autophagy|SOD Support)**

Lifestyle Recommendations

- Calorie Restriction, 12-15 Hour Fasting
- Increased Risk of Parkinson's, Calorie Restriction, 12-15 Hour Fasting

Laboratory Recommendations

- Routine Blood Sugar, Insulin and Hb A1c
- Consider Microbiome Testing If GI Inflammation Present

Gene Information Key

rsID	Gene	"-" variant	"+" variant
rs1007008	SMURF1	C	T
rs10210302	ATG16L1	C	T
rs104893875	PARK1 (alpha synuclein)	C	T
rs2066845	NOD2/CARD15	G	C
rs2241880	ATG16L1	A	G
rs2241880	ATG16L1	A	G
rs26538	ATG12	T	C
rs3798963	PARK2 (Parkin)	A	T
rs429358	APOE	T	C
rs45478900	PARK6 (PINK1)	G	A
rs510432	ATG5	C	T
rs7412	APOE	C	T

Definitions

DEVELOPMENTAL	
APOE: 130	Individuals homozygous for the C/C allele at rs429358 may harbor the APOE E4 allele. Consult with a provider to determine APOE risk allele status.
APOE: Arg176Cys	Individuals homozygous for T/T at rs7412 are assumed to have the E2 allele of the gene APOE. APOE encodes a protein involved in cholesterol and lipid transport and metabolism
ATG12	Autophagy-related 12 protein is part of the core autophagy machinery inside the cell. Autophagy, a form of cellular "recycling" is necessary for many cell functions. ATG12 is specifically involved in turning off the innate immune response. Mutations in the ATG12 gene are predicted to lead to increased activity of the innate immune response, and overall inflammation.
PARK1	PARK1, also known as alpha synuclein, is a highly expressed protein in neurons. Mutations in the PARK1 gene are associated with increased risk of neurodegenerative disorders such as parkinsonism.
PARK2	PARK2 is a protein involved in normal turnover of damaged or old proteins inside the cell. Mutations in the PARK2 gene are associated with heritable Parkinson's disease.
PARK6	The PARK6 protein, also known as PINK1, is a mitochondrial protein kinase. Mutations in PARK6 are associated with autosomal recessive Parkinson's disease.
SMURF-1	The SMURF1 protein is a negative regulator of pathways involved in cell polarity, growth, and differentiation. Normal function of the SMURF1 protein is required for normal development and innate immune function. Polymorphisms in this gene can significantly affect autophagy performance of the cell.
INFLAMMATORY	This enzyme category has significant effects on the inflammatory state of a person's body. Polymorphisms in these specific enzymes will significantly increase the levels of inflammation in the body. By supplementing these enzyme deficiencies, the patient will effectively reduce inflammatory damage to the body.
ATG16L1	The ATG16L1 gene encodes a protein that is a vital component of a protein complex necessary for the cellular phenomena known as autophagy. Autophagy is the process of degrading and cleaning of inert debris of the cell. Weakness in autophagy leads to abnormal accumulation of cellular "garbage" that will eventually affect the cellular function and lead to autophagy related disease states in including many neurological and immunological diseases, DM Type 2 and fatty liver disease.
ATG5	Autophagy-related 5 protein (ATG5) is an important intracellular mediator of the autophagy response. ATG5 is involved in a wide range of "quality control" features inside the cell: autophagy vesicle formation, innate immune system signaling, consumption of damaged mitochondria, and apoptosis. Mutations in the ATG5 gene are associated with numerous neurological, immunological and endocrine syndromes.
NOD2/CARD15	NOD2 is a protein that integrates extracellular sensing of bacterial cell wall components with intracellular pro-inflammatory signaling to the nucleus. Mutations in the NOD2 gene are associated with poor ability to recognize abnormal bacterial pathogens in the intestinal tract and increased risk of intestinal dysbiosis.

Disclaimers

METHODOLOGY AND LIMITATIONS:

Testing for genetic variation/mutation on listed genes was performed using ProFlex PCR and Real-Time PCR with TaqMan® allele-specific probes on the QuantStudio 12K Flex. All genetic testing is performed by GX Sciences, 4150 Freidrich Lane, Ste H, Austin, TX. 78744. This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Test results do not rule out the possibility that this individual could be a carrier of other mutations/variations not detected by this gene mutation/variation panel. Rare mutations surrounding these alleles may also affect our detection of genetic variations. Thus, the interpretation is given as a probability. Therefore, this genetic information shall be interpreted in conjunction with other clinical findings and familial history for the administration of specific nutrients. Patients should receive appropriate genetic counseling to explain the implications of these test results. Details of assay performance and algorithms leading to clinical recommendations are available upon request. The analytical and performance characteristics of this laboratory developed test (LDT) were determined by GX Sciences' laboratory pursuant to Clinical Laboratory Improvement Amendments (CLIA) requirements.
CLIA #: 45D2144988

DISCLAIMER:

This test was developed and its performance characteristics determined by GX Sciences. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. rsIDs for the alleles being tested were obtained from the dbSNP database (Build 142).

DISCLAIMER:

UND Result: If you have received the result Variant undetermined (UND) this indicates that we were not able to determine your carrier status based on your raw data. Please refer to the GX Sciences genetic knowledge database for more information: https://www.gxsciences.com/kb_results.asp

DISCLAIMER:

Report contents and report recommendations are created and approved by GX Sciences. Sole responsibility for the proper use of the information on the GX Sciences report rests with the user, or those professionals with whom the user may consult. Nutrigenomic Testing and Neurobiologix Dietary Supplements are not "Designated Health Services" covered by Medicare or Medicaid and may not be reimbursed under any state or Federal health care program.

DISCLAIMER:

These products are not approved by the Food and Drug Administration and are not intended to diagnose, treat, cure or prevent a disease. These recommendations are for report purposes only and an individual is not required to use such products. These are recommendations only and do not replace the advisement of your own healthcare practitioner.

GX Sciences SNP References

DEVELOPMENTAL SNP References

APOE: 130

• Takei, N., Miyashita, A., Tsukie, T., Arai, H., Asada, T., Imagawa, M., ... Japanese Genetic Study Consortium for Alzheimer Disease. (2009). Genetic association study on and around the APOE in late-onset Alzheimer disease in Japanese. *Genomics*, 93(5), 441–448. <https://doi.org/10.1016/j.ygeno.2009.01.003> • Tejedor, M. T., Garcia-Sobreviela, M. P., Ledesma, M., & Arbones-Mainar, J. M. (2014). The apolipoprotein E polymorphism rs7412 associates with body fatness independently of plasma lipids in middle aged men. *PLoS One*, 9(9), e108605. <https://doi.org/10.1371/journal.pone.0108605> • Rubinsztein, D. C., & Easton, D. F. (1999). Apolipoprotein E Genetic Variation and Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders*, 10(3), 199–209. <https://doi.org/10.1159/000017120>

APOE: Arg176Cys

• Tejedor, M. T., Garcia-Sobreviela, M. P., Ledesma, M., & Arbones-Mainar, J. M. (2014). The apolipoprotein E polymorphism rs7412 associates with body fatness independently of plasma lipids in middle aged men. *PLoS One*, 9(9), e108605. <https://doi.org/10.1371/journal.pone.0108605> • Ruaño, G., Goethe, J. W., Caley, C., Woolley, S., Holford, T. R., Kocherla, M., ... de Leon, J. (2007). Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. *Molecular Psychiatry*, 12(5), 474–482. <https://doi.org/10.1038/sj.mp.4001944>

ATG12

• Anton, Raymond F et al. 2008. "Pharmacogenomics" ed. Yoshiaki Tsuji. *Nature Genetics* 16(1): 268–78. <http://www.ncbi.nlm.nih.gov/pubmed/26671228> (May 14, 2018). • Yuan, Jiali et al. 2017. "Polymorphisms in Autophagy Related Genes and the Coal Workers' Pneumoconiosis in a Chinese Population." *Gene* 632: 36–42. <http://www.ncbi.nlm.nih.gov/pubmed/28844669>.

PARK1

• Jiang, L., Chen, Q., Zhang, Y., Hu, X., Fan, J., Liu, L., ... Hu, G. (2011). PARK1 gene mutation of autosomal dominant Parkinson's disease family. *Neural Regeneration Research*, 6(5), 330–334. • Brookes, A. J. (1999). The essence of SNPs. *Gene*. [https://doi.org/10.1016/S0378-1119\(99\)00219-X](https://doi.org/10.1016/S0378-1119(99)00219-X)

PARK2

• Xu, L., Lin, D., Yin, D., & Koeffler, H. P. (2014). An emerging role of PARK2 in cancer. *Journal of Molecular Medicine*, 92(1), 31–42. <https://doi.org/10.1007/s00109-013-1107-0> • Benitez, B. A., Davis, A. A., Jin, S. C., Ibanez, L., Ortega-Cubero, S., Pastor, P., ... Cruchaga, C. (2016). Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. *Molecular Neurodegeneration*, 11(1), 29. <https://doi.org/10.1186/s13024-016-0097-0>

PARK6

• Khan, N. L., Valente, E. M., Bentivoglio, A. R., Wood, N. W., Albanese, A., Brooks, D. J., & Piccini, P. (2002). Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An 18F-dopa PET study. *Annals of Neurology*, 52(6), 849–853. <https://doi.org/10.1002/ana.10417> • Clarimón, J., Eerola, J., Hellström, O., Peuralinna, T., Tienari, P. J., & Singleton, A. B. (2006). Assessment of PINK1 (PARK6) polymorphisms in Finnish PD. *Neurobiology of Aging*, 27(6), 906–907. <https://doi.org/10.1016/j.neurobiolaging.2005.03.028>

SMURF1

• Yuan, C., Qi, J., Zhao, X., & Gao, C. (2012). Smurf1 protein negatively regulates interferon- γ signaling through promoting STAT1 protein ubiquitination and degradation. *The Journal of Biological Chemistry*, 287(21), 17006–17015. <https://doi.org/10.1074/jbc.M112.341198>

INFLAMMATORY SNP References

ATG16L1

• Role of autophagy genetic variants for the risk of Candida infections Diana C. Rosenthal, Theo S. Plantinga, Marius Farcas, Marije Oosting, Omar J.M. Hamza, William K. Scott, Barbara D. Alexander, John C. Yang, Gregory M. Laird, Leo A.B. Joosten, Jos W. M. van der Meer, John R. Perfect, Bart-Jan Kullberg, Andre J.A.M. van der Ven, Melissa D. Johnson, Mihai G. Netea *Med Mycol*. 2014 May; 52(4): 333–341. Published online 2014 Apr 8. doi: 10.1093/mmy/myt035 • The T300A Crohn's disease risk polymorphism impairs function of the WD40 domain of ATG16L1 Emilio Boada-Romero, Inmaculada Serramito-Gómez, María P. Sacristán, David L. Boone, Raminik J. Xavier, Felipe X. Pimentel-Muñiz *Nat Commun*. 2016; 7: 11821. Published online 2016 Jun 8. doi: 10.1038/ncomms11821 • Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense Kara G. Lassen, Petric Kuballa, Kara L. Conway, Khushbu K. Patel, Christine E. Becker, Joanna M. Peloquin, Eduardo J. Villablanca, Jason M. Norman, Ta-Chiang Liu, Robert J. Heath, Morgan L. Becker, Lola Fagbami, Heiko Horn, Johnathan Mercer, Omer H. Yilmaz, Jacob D. Jaffe, Alykhan F. Shamji, Atul K. Bhan, Steven A. Carr, Mark J. Daly, Herbert W. Virgin, Stuart L. Schreiber, Thaddeus S. Stappenbeck, Raminik J. Xavier *Proc Natl Acad Sci U S A*. 2014 May 27; 111(21): 7741–7746. Published online 2014 May 12. doi: 10.1073/pnas.1407001111 • The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation Agnieszka M Kabat, Oliver J Harrison, Thomas Riffelmaier, Amin E Moghaddam, Claire F Pearson, Adam Laing, Lucie Abeler-Dörner, Simon P Forman, Richard K Grecnis, Quentin Sattentau, Anna Katharina Simon, Johanna Pott, Kevin J Maloy *eLife*. 2016; 5: e12444. Published online 2016 Feb 24. doi: 10.7554/eLife.12444 • T300A polymorphism of ATG16L1 and susceptibility to inflammatory bowel diseases: A meta-analysis Jia-Fei Cheng, Yue-Ji Ning, Wei Zhang, Zong-Hai Lu, Lin Lin *World J Gastroenterol*. 2010 Mar 14; 16(10): 1258–1266. Published online 2010 Mar 14. doi: 10.3748/wjg.v16.i10.1258 • ATG16L1: A multifunctional susceptibility factor in Crohn disease Mohammad Salem, Mette Ammitzboell, Kris Nys, Jakob Benedict Seidelin, Ole Haagen Nielsen *Autophagy*. 2015 Apr; 11(4): 585–594. Published online 2015 Apr 23. doi: 10.1080/15548627.2015.1017187 • The Crohn's disease-associated ATG16L1 variant and Salmonella invasion Jeannette S Messer, Stephen F Murphy, Mark F Logsdon, James P Lodoiceo, Wesley A Grimm, Sarah J Bartulis, Tiphannie P Vogel, Melissa Burn, David L Boone *BMJ Open*. 2013; 3(6): e002790. Published online 2013 Jun 4. doi: 10.1136/bmjopen-2013-002790 • NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease Dylan M Glubb, Richard B Gearty, Murray L Barclay, Rebecca L Roberts, John Pearson, Jacqui I Keenan, Judy McKenzie, Robert W Bentley *World J Gastroenterol*. 2011 Jun 21; 17(23): 2829–2837. Published online 2011 Jun 21. doi: 10.3748/wjg.v17.i23.2829 • Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy Jakob Begun, Kara G. Lassen, Humberto B. Jijon, Leigh A. Baxt, Gautam Goel, Robert J. Heath, Aylwin Ng, Jenny M. Tam, Szu-Yu Kuo, Eduardo J. Villablanca, Lola Fagbami, Marije Oosting, Vinod Kumar, Monica Schenone, Steven A. Carr, Leo A.B. Joosten, Jatin M. Vyas, Mark J. Daly, Mihai G. Netea, Gordon D. Brown, Cisca Wijmenga, Raminik J. Xavier *Cell Rep*. 2015 Jun 30; 11(12): 1905–1918. Published online 2015 Jun 18. doi: 10.1016/j.celrep.2015.05.045 • Polymorphisms in Autophagy Genes Are Associated with Paget Disease of Bone Ricardo Usategui-Martín, Judith García-Aparicio, Luis Corral-Gudino, Ismael Calero-Paniagua, Javier Del Pino-Montes, Rogelio González Sarmiento *PLoS One*. 2015; 10(6): e0128984. Published online 2015 Jun 1. doi: 10.1371/journal.pone.0128984 • Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease Mohammad Salem, Ole Haagen Nielsen, Kris Nys, Shiva Yazdanyar, Jakob Benedict Seidelin *Clin Transl Gastroenterol*. 2015 Nov; 6(11): e122. Published online 2015 Nov 5. doi: 10.1038/ctg.2015.47 • NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease Maria Gazouli, Ioanna Pachoula, Ioanna Panayotou, Gerassimos Mantzaris, George Chrousos, Nicholas P Anagnou, Eleftheria Roma-Giannikou *World J Gastroenterol*. 2010 Apr 14; 16(14): 1753–1758. Published online 2010 Apr 14. doi: 10.3748/wjg.v16.i14.1753 • Impaired Autophagy of an Intracellular Pathogen Induced by a Crohn's Disease Associated ATG16L1 Variant Petric Kuballa, Alan Huett, John D. Rioux, Mark J. Daly, Raminik J. Xavier *PLoS ONE*. 2008; 3(10): e3391. Published online 2008 Oct 13. doi: 10.1371/journal.pone.0003391 • Crohn disease ATG16L1 polymorphism increases susceptibility to infection with *Helicobacter pylori* in humans Deepa Raju, Séamus Hussey, Nicola L. Jones *Autophagy*. 2012 Sep 1; 8(9): 1387–1388. doi: 10.4161/auto.21007 • Crohn disease: A current perspective on genetics, autophagy and immunity Thaddeus S. Stappenbeck, John D. Rioux, Atsushi Mizoguchi, Tatsuya Saitoh, Alan Huett, Arlette Darfeuille-Michaud, Tom Wileman, Noboru Mizushima, Simon Carding, Shizuo Akira, Miles Parkes, Raminik J. Xavier *Autophagy*. 2011 Apr 1; 7(4): 355–374. doi: 10.4161/auto.7.4.13074 • Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients Veronika Csöngéi, Luca Járomi, Enikő Sáfrány, Csilla Sipeky, Lili Magyar, Bernadett Faragó, Judit Bene, Noémi Polgár, Lilla Lakner, Patricia Sarlós, Márta Varga, Béla Melegh *World J Gastroenterol*. 2010 Jan 14; 16(2): 176–183. Published online 2010 Jan 14. doi: 10.3748/wjg.v16.i2.176

ATG5

• Anton, Raymond F et al. 2008. "Pharmacogenomics" ed. Yoshiaki Tsuji. *Nature Genetics* 16(1): 268–78. <http://www.ncbi.nlm.nih.gov/pubmed/26671228> (May 14, 2018). • White, Kirsten A M et al. 2016. "Variants in Autophagy-Related Genes and Clinical Characteristics in Melanoma: A Population-Based Study." *Cancer Medicine* 5(11): 3336–45. <http://www.ncbi.nlm.nih.gov/pubmed/27748080>. • Martin, Lisa J et al. 2012. "Functional Variant in the Autophagy-Related 5 Gene Promotor Is Associated with Childhood Asthma" ed. Dominik Hartl. *PLoS ONE* 7(4): e33454. <http://dx.plos.org/10.1371/journal.pone.0033454>. • Yuan, Jiali et al. 2017. "Polymorphisms in Autophagy Related Genes and the Coal Workers' Pneumoconiosis in a Chinese Population." *Gene* 632: 36–42. <http://www.ncbi.nlm.nih.gov/pubmed/28844669>.

NOD2

• Anton, Raymond F et al. 2008. "Pharmacogenomics" ed. Yoshiaki Tsuji. *Nature Genetics* 16(1): 268–78. <http://www.ncbi.nlm.nih.gov/pubmed/26671228> (May 14, 2018). • Ogura, Yasunori et al. 2001. "A Frameshift Mutation in NOD2 Associated with Susceptibility to Crohn's Disease." *Nature* 411(6837): 603–6. <http://www.ncbi.nlm.nih.gov/pubmed/11385577>. • Nuij, V. J.A.A., M. P. Peppelenbosch, C. J. Woude, and G. M. Fuhler. 2017. "Genetic Polymorphism in ATG16L1 Gene Is Associated with Adalimumab Use in Inflammatory Bowel Disease." *Journal of Translational Medicine* 15(1). • Hugot, Jean-Pierre et al. 2001. "Association of NOD2 Leucine-Rich Repeat Variants with Susceptibility to Crohn's Disease." *Nature* 411(6837): 599–603. <http://www.ncbi.nlm.nih.gov/pubmed/11385576>.